BlackRock
CYCN

BlackRock’s Cyclerion Therapeutics CYCN Stock Holding History

BlackRock’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.9K Hold
16,797
– – ﹤0.01% 5150
2026
Q1 		$26K Hold
16,797
– – ﹤0.01% 5255
2025
Q4 		$21.3K Hold
16,797
– – ﹤0.01% 5207
2025
Q3 		$38.6K Hold
16,797
– – ﹤0.01% 5023
2025
Q2 		$48.9K Hold
16,797
– – ﹤0.01% 4992
2025
Q1 		$42K Hold
16,797
– – ﹤0.01% 4950
2024
Q4 		$54.1K Hold
16,797
– – ﹤0.01% 4931
2024
Q3 		$43.5K Sell
16,797
-372
-2% -$1.09K ﹤0.01% 4840
2024
Q2 		$39.5K Hold
17,169
– – ﹤0.01% 4907
2024
Q1 		$54.9K Hold
17,169
– – ﹤0.01% 4853
2023
Q4 		$57.5K Sell
17,169
-831
-5% -$2.4K ﹤0.01% 4942
2023
Q3 		$61.6K Hold
18,000
– – ﹤0.01% 4966
2023
Q2 		$74.2K Sell
18,000
-1
-0% -$5 ﹤0.01% 4998
2023
Q1 		$156K Sell
18,001
-14
-0.1% -$177 ﹤0.01% 4846
2022
Q4 		$236K Sell
18,015
-19
-0.1% -$225 ﹤0.01% 4804
2022
Q3 		$310K Sell
18,034
-45
-0.2% -$773 ﹤0.01% 4859
2022
Q2 		$198K Sell
18,079
-3,990
-18% -$57.2K ﹤0.01% 5031
2022
Q1 		$490K Sell
22,069
-189
-0.8% -$4.55K ﹤0.01% 4871
2021
Q4 		$765K Buy
22,258
+500
+2% +$23.6K ﹤0.01% 4746
2021
Q3 		$1.34M Sell
21,758
-49
-0.2% -$3.21K ﹤0.01% 4480
2021
Q2 		$1.7M Sell
21,807
-62,467
-74% -$3.91M ﹤0.01% 4344
2021
Q1 		$4.7M Buy
84,274
+4,068
+5% +$306K ﹤0.01% 3969
2020
Q4 		$4.91M Buy
80,206
+4,039
+5% +$275K ﹤0.01% 3717
2020
Q3 		$9.26M Sell
76,167
-2,176
-3% -$249K ﹤0.01% 3261
2020
Q2 		$9.26M Sell
78,343
-1,120
-1% -$93.6K ﹤0.01% 3223
2020
Q1 		$4.21M Sell
79,463
-1,371
-2% -$97.8K ﹤0.01% 3426
2019
Q4 		$4.4M Buy
80,834
+5,361
+7% +$501K ﹤0.01% 3547
2019
Q3 		$18.3M Buy
75,473
+1,586
+2% +$343K ﹤0.01% 2861
2019
Q2 		$16.9M Buy
+73,887
New +$20.9M ﹤0.01% 2940

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

BlackRock's CYCN Position: Q2 2026 in Review

BlackRock held its Cyclerion Therapeutics (CYCN) position steady in Q2 2026 at 16,797 shares worth $56.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5150.

BlackRock first reported a position in CYCN in Q2 2019 and has held it in 29 quarters since. The position peaked at $18.3M in Q3 2019. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • BlackRock held 16,797 shares of Cyclerion Therapeutics worth $56.9K as of Q2 2026.
  • BlackRock left its Cyclerion Therapeutics share count unchanged in Q2 2026.
  • Cyclerion Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5150 holding.
  • BlackRock first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • BlackRock's Cyclerion Therapeutics position peaked at $18.3M in Q3 2019.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.